SYNCROSOME

Executive Summary

SYNCROSOME is a French preclinical contract research organization (CRO) founded in 2013 and headquartered in Paris. Specializing in drug efficacy studies and bioavailability/CNS-PK studies, the company leverages a portfolio of over 15 validated in vivo disease models spanning CNS, cardiovascular, gastroenterology, metabolic, and respiratory disorders. In October 2023, SYNCROSOME was acquired by the ETAP-Lab Group, a strategic move expected to enhance its service offerings and expand its client base. The acquisition provides SYNCROSOME with access to ETAP-Lab's broader capabilities and network, positioning it to capture greater market share in the preclinical CRO space, particularly for CNS-targeted therapies. With a strong focus on neuroscience and drug delivery, the company is well-positioned to support the growing demand for preclinical testing services, driven by increased R&D spending in biopharma. Despite being a private firm with limited financial disclosure, its established track record and validated models offer a reliable service platform for drug discovery clients.

Upcoming Catalysts (preview)

• Q2 2026Integration synergies with ETAP-Lab Group leading to new service packages70% success
• Q4 2026Expansion of in vivo model portfolio into immuno-oncology or rare diseases50% success
• Q3 2026Major contract win with a top-20 pharma for CNS drug development40% success